SCNLF

Healthcare Biotechnology

Scancell Holdings plc

$0.14

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

191.29M

Avg Volume

6,713

EPS

-$0.01

52W High

$0.33

52W Low

$0.12

Div. Yield

0.0%

Valuation

P/B Ratio

-13.30

P/S Ratio

40.61

EV/EBITDA

-11.88

EV/Revenue

32.68

Margins

Gross Margin 94.9%

Operating Margin (283.3%)

Net Margin (117.0%)

EBITDA Margin (275.2%)

Growth & Returns

Return on Assets

(52.2%)

Liquidity & Leverage

Current Ratio

0.56

Quick Ratio

0.56

Total Cash

8.57M

Total Debt

16.18M

About

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.